Attenuation markers of a candidate dengue type 2 vaccine virus, strain 16681 (PDK-53), are defined by mutations in the 5' noncoding region and nonstructural proteins 1 and 3
about
Subversion of innate defenses by the interplay between DENV and pre-existing enhancing antibodies: TLRs signaling collapseInhibition of dengue virus serotypes 1 to 4 in vero cell cultures with morpholino oligomersStereophysicochemical variability plots highlight conserved antigenic areas in FlavivirusesWest Nile Virus Temperature Sensitivity and Avian Virulence Are Modulated by NS1-2B PolymorphismsDengue virus 1 in Buenos Aires from 1999 to 2010: towards local spreadChimeric dengue type 2 (vaccine strain PDK-53)/dengue type 1 virus as a potential candidate dengue type 1 virus vaccineChimeric Dengue 2 PDK-53/West Nile NY99 Viruses Retain the Phenotypic Attenuation Markers of the Candidate PDK-53 Vaccine Virus and Protect Mice against Lethal Challenge with West Nile VirusChemical mutagenesis of dengue virus type 4 yields mutant viruses which are temperature sensitive in vero cells or human liver cells and attenuated in mice.Neuroadapted yellow fever virus 17D: genetic and biological characterization of a highly mouse-neurovirulent virus and its infectious molecular cloneConstruction, safety, and immunogenicity in nonhuman primates of a chimeric yellow fever-dengue virus tetravalent vaccine.Infectious cDNA clone of the epidemic west nile virus from New York CityA Live, Attenuated Dengue Virus Type 1 Vaccine Candidate with a 30-Nucleotide Deletion in the 3' Untranslated Region Is Highly Attenuated and Immunogenic in MonkeysYellow Fever Virus/Dengue-2 Virus and Yellow Fever Virus/Dengue-4 Virus Chimeras: Biological Characterization, Immunogenicity, and Protection against Dengue Encephalitis in the Mouse ModelAmerican Genotype Structures Decrease Dengue Virus Output from Human Monocytes and Dendritic CellsCharacterization of a small plaque variant of West Nile virus isolated in New York in 2000Dengue 2 PDK-53 Virus as a Chimeric Carrier for Tetravalent Dengue Vaccine DevelopmentNeuroadapted Yellow Fever Virus 17D: Determinants in the Envelope Protein Govern Neuroinvasiveness for SCID MiceIdentification of genetic determinants of a tick-borne flavivirus associated with host-specific adaptation and pathogenicityStructural and Functional Studies of the Promoter Element for Dengue Virus RNA ReplicationCharacterization of Recombinant Dengue-2 Virus Derived from a Single Nucleotide Substitution in the 5′ Noncoding RegionDengue structure differs at the temperatures of its human and mosquito hostsA rapid immunization strategy with a live-attenuated tetravalent dengue vaccine elicits protective neutralizing antibody responses in non-human primatesA Reverse Genetics Platform That Spans the Zika Virus Family TreeThe 5' and 3' Untranslated Regions of the Flaviviral Genome.Dengue vaccines: state of the art.Development of DENVax: a chimeric dengue-2 PDK-53-based tetravalent vaccine for protection against dengue fever.Genetic and phenotypic characterization of manufacturing seeds for a tetravalent dengue vaccine (DENVax).Treatment of AG129 mice with antisense morpholino oligomers increases survival time following challenge with dengue 2 virus.Efficacy of a tetravalent chimeric dengue vaccine (DENVax) in Cynomolgus macaquesPatterns of epistasis in RNA viruses: a review of the evidence from vaccine design.Cell-specific adaptation of two flaviviruses following serial passage in mosquito cell culture.Dengue vaccine: priorities and progress.Safety and Immunogenicity of a Live Attenuated Tetravalent Dengue Vaccine Candidate in Flavivirus-Naive Adults: A Randomized, Double-Blinded Phase 1 Clinical Trial.Development of Dengue type-2 virus replicons expressing GFP reporter gene in study of viral RNA replicationCD8+ T-cell Responses in Flavivirus-Naive Individuals Following Immunization with a Live-Attenuated Tetravalent Dengue Vaccine Candidate.Safety and immunogenicity of a recombinant live attenuated tetravalent dengue vaccine (DENVax) in flavivirus-naive healthy adults in Colombia: a randomised, placebo-controlled, phase 1 studyA phosphomimetic-based mechanism of dengue virus to antagonize innate immunity.Molecular determinants of plaque size as an indicator of dengue virus attenuationA chimeric dengue virus vaccine using Japanese encephalitis virus vaccine strain SA14-14-2 as backbone is immunogenic and protective against either parental virus in mice and nonhuman primates.Challenges in reducing dengue burden; diagnostics, control measures and vaccines.
P2860
Q21144516-C90CD0DB-33BF-486E-90F3-7948CBAFCF6BQ24520621-52B545BA-15B5-4748-BCE0-8347FDB311ADQ24804265-F2CA41CF-8487-4362-B26E-977F7E97DC3FQ26513109-F4F792A5-1234-4D11-A2A6-F33660833B52Q27334332-752C3877-79B4-4DC2-8408-6287E96487A1Q27469646-8D0C9B53-B023-4572-AA64-76BC18805926Q27469831-F19BDAEF-872C-442E-9435-C9F223A8B9E2Q27469872-8FD0CC25-3F06-467A-BEE7-701811D106D5Q27469879-6778EC0D-8E6E-4F97-9215-93E192F66FF2Q27469921-D03993F0-77D6-46B9-8840-9A184F777401Q27472878-6A409DCF-DEC4-4051-88BB-274114B65DB6Q27473080-5C0C471E-6058-4B7A-945E-A46897536B2FQ27473317-09CC7D14-D8ED-4835-A753-AB6680C23E26Q27473379-CF7DF705-CCCD-4156-94FF-B3F73EA98C28Q27485096-5852D1F2-B97B-4CF8-865E-A63338007F0AQ27485759-54DA3236-5D89-4745-BAD2-4B994C1FAEEFQ27486896-740FF510-4036-41DE-B5D4-D523A39852D5Q27487383-DE80F5EC-D7CB-4DD6-85C5-BB4A0CC0F91DQ27487528-79C21F24-1BE9-4533-9115-95AD9EEE13E8Q27491304-1BC2CFEB-D6EC-445E-8A6B-6F7A38F2BA4DQ27677270-CE0E3B5A-6853-4152-89C3-30FA871C510CQ28241909-C52DADE4-BD6D-4401-B0BA-714492CC3985Q28954816-08404FAC-1473-4281-AD63-B04B9C6BD1C1Q32183359-007E4329-188B-4DDC-AFFE-28334ADF573AQ34109652-E91EDE78-53DB-4168-AAC2-1335EC0208D7Q34202440-6D4F5344-F150-4CA3-B7E7-1BAAB9D451ECQ34759091-FB7E4FC1-B72B-4FED-9BB7-29EE58C8BE80Q34787775-B03F42B6-6B27-4101-9533-E2DB75568CC7Q35031833-277F19C6-A807-41BB-BC49-010DD0E6D7B8Q35593849-03C91525-A10B-4C33-9909-215F4E781C14Q35645969-8B600DB7-BF6E-4FDA-BCAF-2FAE873E5C31Q35964754-494A661F-77F0-424D-BA55-B81C63688F3EQ36024479-7473FCD4-0821-47A9-A351-FF638C13E33BQ36092279-9AAF2A51-A2C5-4C98-88C2-27BC7D4CFC85Q36208591-D4CE70ED-53BD-47F3-865E-01A8EAEF084AQ36288109-D43DE7C0-9C9E-4A6B-9650-26A49AFFB10DQ36813821-194DC142-66D0-442C-80CF-9D15B3AA8EE3Q36906525-5EA3D993-77D6-42D9-B96A-6C4B7B843524Q37336762-11A2C790-99D7-4211-BA90-949FA5217634Q38140035-DA75CAD8-5222-462D-A724-A2D02E0B1526
P2860
Attenuation markers of a candidate dengue type 2 vaccine virus, strain 16681 (PDK-53), are defined by mutations in the 5' noncoding region and nonstructural proteins 1 and 3
description
2000 nî lūn-bûn
@nan
2000 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2000 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2000年の論文
@ja
2000年論文
@yue
2000年論文
@zh-hant
2000年論文
@zh-hk
2000年論文
@zh-mo
2000年論文
@zh-tw
2000年论文
@wuu
name
Attenuation markers of a candi ...... nonstructural proteins 1 and 3
@ast
Attenuation markers of a candi ...... nonstructural proteins 1 and 3
@en
Attenuation markers of a candi ...... nonstructural proteins 1 and 3
@nl
type
label
Attenuation markers of a candi ...... nonstructural proteins 1 and 3
@ast
Attenuation markers of a candi ...... nonstructural proteins 1 and 3
@en
Attenuation markers of a candi ...... nonstructural proteins 1 and 3
@nl
prefLabel
Attenuation markers of a candi ...... nonstructural proteins 1 and 3
@ast
Attenuation markers of a candi ...... nonstructural proteins 1 and 3
@en
Attenuation markers of a candi ...... nonstructural proteins 1 and 3
@nl
P2093
P2860
P3181
P1433
P1476
Attenuation markers of a candi ...... nonstructural proteins 1 and 3
@en
P2093
D J Gubler
D J Pierro
N Bhamarapravati
R M Kinney
S Butrapet
P2860
P304
P3181
P356
10.1128/JVI.74.7.3011-3019.2000
P577
2000-04-01T00:00:00Z